Board
Screen
Heat
Cal
Watch
News
Blog
TV
News

ZetaChain Proposes About 55 Million ZETA Burn, No Sales of Newly Unlocked Foundation ZETA in 2027

ZetaChain's governance vote on burning roughly 55 million ZETA tokens and committing to no sales of newly unlocked Foundation ZETA in 2027 closes Saturday, Nov. 7, 2026. The…
Nov 5, 11:33 AM ·

Thailand to block Bitget in December over unlicensed crypto trading

Thailand's SEC filed a criminal complaint against BG Limited, the operator of crypto exchange Bitget, alleging it ran an unlicensed digital asset business for Thai users from 2022…
Nov 5, 11:33 AM ·

Can Argan Keep Its Earnings Streak Alive as Backlog Slips Further?

Argan (AGX) posted 61.5% revenue growth with expanding margins, supported by strong power demand and $1.03 billion in liquidity. However, the company's backlog slipped further…
Nov 5, 11:31 AM ·

AI in Ophthalmology Market Size, Share, and Trends Analysis 2026-2036: Evaluates AI Adoption Across Ophthalmic Imaging, Diagnostics, Surgical Planning, and Clinical Workflows

ResearchAndMarkets.com has added a global AI in ophthalmology market report covering 2026-2036, estimating the market at USD 430 (unit unspecified in the excerpt). The forecast…
Nov 5, 11:30 AM

Brunswick annonce une augmentation de la taille de son placement sous le régime de la dispense pour financement de l’émetteur coté et son placement privé simultané annoncés précédemment pour un produit brut pouvant atteindre 20 million $

Brunswick Exploration (TSX-V: BRW) increased its previously announced marketed private placement to gross proceeds of up to C$17.84 million, citing strong investor demand, with…
Nov 5, 11:30 AM ·

Repligen: 3 Key Takeaways for Long-Term Investors

Repligen (RGEN) reported third-quarter revenue of $209 million. The company expects its BioLife unit to contribute $24 million in fourth-quarter revenue.
Nov 5, 11:30 AM ·

IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization

Late-breaking ELSPIRE data presented at The Liver Meeting 2026 and published in HEPATOLOGY show 85.3% of IQIRVO-treated patients achieved ALP normalization at Week 52 in primary…
Nov 5, 11:30 AM

Here's the 1 Stock I'd Most Want to Buy If the Market Crashes

Viking Therapeutics (VKTX) is highlighted as a stock to watch, with its ongoing phase 3 trials for lead drug VK2735 cited as the key catalyst for shareholder value. The article…
Nov 5, 11:30 AM ·

Pluxee convenes its Fiscal 2026 Annual General Meeting of Shareholders

Pluxee has published the agenda and explanatory notes for its Fiscal 2026 Annual General Meeting of Shareholders, scheduled for December 17, 2026 at 2:00 pm CET in…
Nov 5, 11:30 AM

Les données «late-breaking» sur IQIRVO® relèvent les ambitions thérapeutiques dans la CBP : plus de 85 % des patients traités obtiennent une normalisation des PAL

Ipsen (Euronext: IPN; ADR: IPSEY) reported late-breaking Phase III ELSPIRE data showing IQIRVO achieved alkaline phosphatase (ALP) normalization in 85.3% of patients at week 52…
Nov 5, 11:30 AM
AI in Ophthalmology Market Size, Share, and Trends Analysis 2026-2036: Evaluates AI Adoption Across Ophthalmic Imaging, Diagnostics, Surgical Planning, and Clinical Workflows
Nov 5, 11:30 AM·
Medium Neutral

Sources

Summarized by i88

Tickers

Summary

ResearchAndMarkets.com has added a global AI in ophthalmology market report covering 2026-2036, estimating the market at USD 430 (unit unspecified in the excerpt). The forecast evaluates AI adoption across ophthalmic imaging, diagnostics, surgical planning and clinical workflows. No tickers were cited in the release.

ResearchAndMarkets.com Adds Global AI in Ophthalmology Market Report Covering 2026–2036

ResearchAndMarkets.com has added a report titled “AI in Ophthalmology Market Size, Share and Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)” to its offering, according to a release dated Nov. 5, 2026, from Dublin.

The global AI in ophthalmology market is estimated at USD 430, according to the release. The excerpt does not specify the unit for that figure.

Scope of the Forecast

The report’s title indicates it evaluates AI adoption across four areas:

  • Ophthalmic imaging
  • Diagnostics
  • Surgical planning
  • Clinical workflows

The forecast period covered by the report runs from 2026 to 2036.

Release Details

The announcement was distributed via GlobeNewswire. No tickers or company-specific financial data were cited in the release.